Find Approved Drugs for Genetic Disease in Clinical Development in GERMANY

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antihemophilic factor recombinant PEGylated-aucl

            Therapeutic Area: Genetic Disease Product Name: Jivi

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 15, 2020

            Details:

            Bayer presented data comparing the pharmacokinetic profiles of two extended half-life recombinant factor VIII (FVIII) therapies, Jivi® (antihemophilic factor [recombinant] PEGylated-aucl) and Adynovate® in people living with hemophilia A.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Koate DVI

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: WuXi Biologics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition January 16, 2020

            Details:

            First drug product facility in Europe to complement WuXi Biologics’ existing commercial manufacturing capacities. WuXi Biologics will be the back-up manufacturer for Kovaltry™ of Bayer.